Firm Warned On Spiked Supplements After Closing Door To FDA Official
This article was originally published in The Tan Sheet
Executive Summary
FDA reminds Nova Products of its obligation to allow access to agency inspectors in a warning letter that also notes the firm’s products are unapproved new drugs due to the presence of sildenafil and tadalafil and are misbranded because labeling fails to bear adequate directions for the ingredients’ intended use.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.